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Abstract
Background: Bortezomib is a proteasome inhibitor that has shown impressive efficacy in the treatment of multiple
myeloma. In mice, the addition of dextran sulfate sodium (DSS) to drinking water leads to acute colitis that can serve as an
experimental animal model for human ulcerative colitis.
Methodology/Principal Findings: Bortezomib treatment was shown to potently inhibit murine DSS-induced colitis. The
attenuation of DSS-induced colitis was associated with decreased inflammatory cell infiltration in the colon. Specifically,
bortezomib-treated mice showed significantly decreased numbers of CD4
+ and CD8
+ T cells in the colon and mesenteric
lymph nodes. Bortezomib treatment significantly diminished interferon (IFN)-c expression in the colon and mesenteric
lymph nodes. Furthermore, cytoplasmic IFN-c production by CD4
+ and CD8
+ T cells in mesenteric lymph nodes was
substantially decreased by bortezomib treatment. Notably, bortezomib enhanced T cell apoptosis by inhibiting nuclear
factor-kB activation during DSS-induced colitis.
Conclusions/Significance: Bortezomib treatment is likely to induce T cell death, thereby suppressing DSS-induced colitis by
reducing IFN-c production.
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Introduction
Ulcerative colitis is an inflammatory bowel disease character-
ized by pathologic mucosal damage and ulceration, which can
involve the rectum and extend proximally [1]. Although its
etiology and pathogenesis have not yet been identified, inappro-
priate activation of the mucosal immune system has been found to
play an important role in mucosal inflammation. At sites of
intestinal inflammation, granulocytes and macrophages produce
high levels of pro-inflammatory cytokines, including interleukin
(IL)-1b, IL-6, and tumor necrosis factor (TNF)-a [2,3], which are
directly involved in the pathogenesis of ulcerative colitis.
The oral administration of dextran sulfate sodium (DSS)
solution to rodents is widely employed as a model of human
ulcerative colitis, because it causes acute inflammatory reactions
and ulceration in the entire colon similar to that observed in
patients [4,5]. Mice exposed to DSS in drinking water develop
inflammation only in the large intestine and show signs such as
diarrhea, hematochezia, and body weight loss with histologic
findings including inflammatory cell infiltration, erosion, ulcera-
tion, and crypt abscesses. Furthermore, increased production of
pro-inflammatory cytokines, including interferon (IFN)- c, TNF-a,
IL-1, IL-6, IL-12, and IL-17, has been found in the colon of mice
with DSS-induced colitis [6,7].
The major intracellular pathway for protein degradation is the
ubiquitin-proteasome pathway [8]. Proteasomes are large multi-
meric protease complexes located in both the cytoplasm and nuclei
that selectively and timely degrade most cellular proteins [9,10].
The 26S proteasome consists of a central 20S core and two
19S regulatory complexes. Upon stimulation, the formation of
immunoproteasomes is induced. The ubiquitination of target
proteins is an important mechanism for the discriminatory nature
of protein degradation by proteasomes [10]. Proteasome inhibitors
have received much attention because of their potent anti-tumor
activity [11]. In particular, bortezomib, a boronic acid dipeptide
derivative, is a specific protease inhibitor that has recently been
approved for the treatment of relapsed multiple myeloma, a
plasma cell neoplasia, because of its direct growth-inhibitory and
apoptotic effects on this cancer [11,12]. Furthermore, bortezomib
is effective in the treatment of allograft rejection, graft-versus-host
disease, contact hypersensitivity responses, and lupus-like disease
inmice[13–16].Proteasomeinhibitorsinduceapoptosis inactivated
and proliferating, but not resting, T cells [17,18], suggesting one
possible mechanism for the suppression of T cell-mediated immune
responses by bortezomib. In this study, the effect of bortezomib in
ulcerative colitis was examined using DSS-induced mouse colitis.
Results
Bortezomib treatment attenuates DSS-induced colitis
To assess the therapeutic effect of bortezomib in DSS-induced
colitis, we treated mice with 3% DSS for 7 days and quantitatively
evaluated the severity of intestinal injury by measuring body
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twice weekly with bortezomib or phosphate buffered saline (PBS)
control starting 2 days before DSS administration. DAI scores
were based on weight loss, stool consistency, and bleeding.
Statistically significant body weight loss was first observed in
DSS-treated mice on day 6 (Figure 1A). Bortezomib treatment
significantly attenuated body weight loss compared with control-
treated mice and delayed the increase in DAI scores by 1 day from
day 4 (control-treated mice) to day 5 (bortezomib-treated mice)
(Figure 1B). DAI scores were also significantly higher in
bortezomib-treated mice than in control-treated mice from day
5–7. Each element of the DAI score showed the same trend as the
overall DAI score, suggesting that bortezomib treatment sup-
pressed DSS-induced colitis in mice.
Figure 1. Bortezomib suppressed the severity of DSS-induced
colitis. Mice ingested either DSS solution or normal drinking water.
Mice were treated with 200 ml of bortezomib (0.75 mg/kg) or PBS
(control) intravenously twice weekly, starting 2 days prior to DSS
administration. The severity of intestinal injury was evaluated by
quantitatively measuring body weight (A) and DAI scores (B). DAI
scores were based on weight loss, stool consistency, and bleeding.
Values represent means (6SEM) from $4 mice per group. Significant
differences between sample means are indicated: *P,0.05; **P,0.01.
Similar results were obtained in at least two independent experiments.
doi:10.1371/journal.pone.0034587.g001
Figure 2. Bortezomib treatment reduced the severity of DSS-
induced colitis. Colon sections were harvested from mice treated with
bortezomib or control after ingestion of either DSS solution or normal
drinking water for 7 days, and stained with hematoxylin and eosin. (A)
Representative colon sections at 7 days after induction of colitis. (B)
Histologic sections were blindly scored on a scale of 0–4 for severity of
colitis. Values represent means (6SEM) from $4 mice per group.
Significant differences between sample means are indicated:
**P,0.01**. Results represent one of two independent experiments
producing similar results.
doi:10.1371/journal.pone.0034587.g002
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injury was assessed histopathologically. Following the 7-day period
of ingestion of 3% DSS or normal drinking water, colons were
removed for histopathologic evaluation (Figure 2A). DSS treat-
ment induced epithelial injury and increased mononuclear cell
infiltration and inflammatory changes in submucosal tissues of
control-treated mice, but these changes were less severe in
bortezomib-treated mice. The pathologic scores were significantly
lower in bortezomib-treated mice than in control-treated mice
(P,0.01; Figure 2B). Thus, bortezomib treatment reduced DSS-
induced colitis both clinically and histopathologically.
Bortezomib inhibits T cell accumulation during DSS-
induced colitis
The profile of infiltrating cells in the colon was further examined
immunohistologically. Seven days after DSS administration,
neutrophil numbers were significantly decreased in bortezomib-
treated mice relative to control-treated mice (23% decrease,
P,0.05; Figure 3A). The numbers of CD4
+ and CD8
+ T cells
were also significantly lower in mice treated with bortezomib than
in control mice (38% decrease, P,0.05 and 41% decrease,
P,0.05, respectively), but there were no significant differences in
numbers of B cells or macrophages. Thus, bortezomib treatment
reduced both neutrophil and T cell infiltration in the colon.
To determine whether bortezomib treatment altered the
populations of T cells and B cells in mesenteric lymph nodes
during DSS-induced colitis, the numbers of CD4
+, CD8
+, and
B220
+ cells in mesenteric lymph nodes were assessed by flow
cytometry 7 days after DSS administration. Mice treated with
bortezomib had fewer CD4
+ and CD8
+ T cells than control mice
(42% decrease, P,0.05 and 41% decrease, P,0.05, respectively;
Figure 3B). Thus, bortezomib treatment decreased the numbers of
both CD4
+ and CD8
+ T cells in mesenteric lymph nodes.
Bortezomib reduces IFN-c production during DSS-
induced colitis
The effect of bortezomib treatment on cytokine expression
during DSS-induced colitis was examined by assessing the mRNA
expression of several cytokines in control and bortezomib-treated
mice. Colons and mesenteric lymph nodes were harvested 7 days
after the induction of colitis, and the expression of IFN-c, IL-6, IL-
17, IL-4, and IL-10 mRNA was quantified by real-time PCR.
Bortezomib treatment significantly decreased IFN-c colon mRNA
levels by 70% and IL-6 colon mRNA levels by 58% compared
with control mice (P,0.05, Figure 4A). By contrast, mRNA
expression of IL-17, IL-4 and IL-10 in the colons was not affected
by bortezomib treatment. In mesenteric lymph nodes, IFN-c
transcripts of bortezomib-treated mice were significantly decreased
relative to those of control mice (75% decrease, P,0.01;
Figure 4B). IL-6, IL-17, IL-4 and IL-10 mRNA expression in
mice treated with bortezomib was comparable to control mice.
Thus, bortezomib treatment substantially decreased IFN-c mRNA
levels during DSS-induced colitis.
Bortezomib diminishes T cell IFN-c production during
DSS-induced colitis
Intracellular cytokine staining was used to assess whether
bortezomib treatment affected IFN-c production from mesenteric
lymph node CD4
+ and CD8
+ T cells. Bortezomib treatment
significantly reduced the frequency (43% decrease, P,0.05) and
number (53% decrease, P,0.01) of IFN-c-producing CD4
+ T cells
compared with control mice (Figure 5A). Furthermore, the
frequency and number of CD8
+ T cells in mice treated with
bortezomib were 40% (P,0.05) and 66% (P,0.01) lower,
respectively, than in control mice (Figure 5B). Thus, bortezomib
treatment diminished T cell IFN-c production during DSS-
induced colitis.
Bortezomib induces T cell apoptosis by inhibiting NF-kB
activation during DSS-induced colitis
To determine whether bortezomib treatment induced T cell
apoptosis, thereby suppressing DSS-induced colitis, the percent-
ages of Annexin-V/7-AAD
+ CD4
+ and CD8
+ T cells in
mesenteric lymph nodes were assessed 7 days after the induction
of colitis. In mice treated with bortezomib, the numbers of
Annexin-V/7-AAD
+ CD4
+ and CD8
+ T cells were significantly
increased compared with control-treated mice (2.7-fold, P,0.05
and 3.2-fold, P,0.01, respectively; Figure 6A). As proteasome
inhibitors counteract NF-kB activation by interfering with the
proteasomal degradation of IkB proteins, we also assessed the
transcriptional activity of NF-kB using real-time PCR for NF-kB-
induced IkBa mRNA. IkB mRNA levels of CD4
+ and CD8
+ T
Figure 3. Profile of infiltrating cells in the colon and mesenteric
lymph nodes during DSS-induced colitis in mice treated with
bortezomib or control. (A) The numbers of neutrophils, CD4
+ T cells,
CD8
+ T cells, B220
+ B cells, and F4/80
+ macrophages per one field of
view (6200) in the colon were counted. (B) Bortezomib affects CD4
+
and CD8
+ T cell numbers in mesenteric lymph nodes during DSS-
induced colitis. Bar graphs indicate CD4
+ T cells, CD8
+ T cells, and B220
+
cells in mesenteric lymph nodes 7 days after induction of colitis. A, B)
Values represent means (6 SEM) from $4 mice per group. Significant
differences between sample means are indicated: *P,0.05. Similar
results were obtained in at least two independent experiments.
doi:10.1371/journal.pone.0034587.g003
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were significantly enhanced compared with control-treated mice
(2.5-fold, P,0.05 and 3.2-fold, P,0.01, respectively; Figure 6B).
Thus, NF-kB inhibition is likely to contribute to bortezomib-
induced cell death in T cells, thereby suppressing DSS-induced
colitis.
Discussion
The results of this study demonstrate that bortezomib treatment
inhibits DSS-induced colitis in mice (Figures 1 and 2). The
suppression of DSS-induced colitis by bortezomib treatment
correlated with a decrease in CD4
+ and CD8
+ T cell accumulation
both in the colon and mesenteric lymph nodes (Figure 3).
Remarkably, bortezomib treatment significantly reduced IFN-c
mRNA expression in the colon and mesenteric lymph nodes,
while IL-17, IL-4 and IL10 mRNA expression was not affected
(Figure 4). Consistently, IFN-c production from CD4
+ and CD8
+
T cells in mesenteric lymph nodes was inhibited by bortezomib
treatment (Figure 5). Thus, bortezomib treatment attenuated DSS-
induced colitis by inhibiting excessive IFN-c production from
CD4
+ and CD8
+ T cells.
The immunoproteasome subunit LMP7 is critical for protea-
some activity [19], and it was recently reported that LMP7-
deficiency is associated with reduced severity of DSS-induced
colitis in mice [20]. Patients with inflammatory bowel disease
exhibit high levels of LMP7 in the inflamed gut [21], and their
increased proteasome activity induced by high levels of expression
of immunoproteasome subunits mediates sustained activation of
NF-kB [22]. These results suggest that proteasome inhibitors may
ameliorate inflammatory bowel disease. In this study, bortezomib
administration substantially reduced the severity of DSS-induced
colitis as well as significantly enhancing apoptosis and IkB
expression of CD4
+ and CD8
+ T cells during DSS-induced colitis
(Figure 6). Thus, NF-kB inhibition is likely to contribute to
bortezomib-induced cell death in T cells, thereby suppressing
DSS-induced colitis.
Bortezomib treatment of mice with lupus-like disease signifi-
cantly improves the disease severity by reducing the numbers
of both CD4
+ and CD8
+ T cells in the spleen [14]. Bortezomib
treatment also demonstrates significant protection from acute
graft-versus-host disease in a murine allogeneic bone marrow
transplantation model by inhibiting allogeneic T cell proliferation
[16]. By contrast, bortezomib administration largely eliminates
plasma cells but not T cells or B cells in murine models of human
systemic lupus erythematosus [14]. In the current study, bortezomib
treatment reduced the numbers of CD4
+ and CD8
+ T cells, but not
B cells or macrophages during DSS-induced colitis. It has been
reported that proliferating T cells are more sensitive to bortezomib-
mediated cytotoxity than resting T cells [16,17]. Proteasome
inhibitors induce endoplasmic reticulum stress-induced apoptosis
in multiple myeloma cells as a result of the terminal unfolded
protein response [23], while inhibition of proteasome activities by
proteasome inhibitors induces apoptosis preferentially in rapid
proliferating neoplastic cells [24]. Thus, bortezomib treatment
is likely to eliminate only excessively proliferating immune cells,
thereby suppressing harmful inflammatory responses.
Proteasome inhibition using bortezomib has recently emerged
as an effective anticancer therapy [11]. Thus far, the therapeutic
feasibility of protease inhibition in inflammatory and autoimmune
diseases has been revealed only in murine models of human
systemic lupus erythematosus [14], experimental autoimmune
Figure 4. Bortezomib treatment affects cytokine production in DSS-induced colits. Cytokine mRNA expression in the colon (A) and
mesenteric lymph nodes (B) in mice treated with bortezomib or control during DSS-induced colitis. Colon tissue and mesenteric lymph nodes were
collected from control- or bortezomib-treated mice 7 days following DSS administration. Transcript levels were quantified by real-time PCR analysis
and were normalized with an internal control. Values represent means (6 SEM) from $4 mice of each group. Significant differences between sample
means are indicated; *P,0.05, **P,0.01. Results represent one of two independent experiments producing similar results.
doi:10.1371/journal.pone.0034587.g004
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and contact dermatitis [13]. In the current study, bortezomib
treatment in mice resulted in attenuated DSS-induced colitis,
suggesting that bortezomib may also be effective for the treatment
of human ulcerative colitis. Patients with this disease are generally
treated with anti-inflammatory and immunosuppressive drugs,
antizbiotics, and biologics such as anti-tumor necrosis factor
therapies and/or surgery. However, such therapies do not cure the
disease and patients suffer a life-long illness. Further studies are
needed to determine the precise mechanisms by which bortezomib
treatment reduces the severity of DSS-induced colitis. Nonetheless,
if the efficacy seen in mice translates to humans, the current results
may provide new insights and therapeutic approaches for treating
ulcerative colitis.
Materials and Methods
Ethics statement
All animal studies and procedures were approved by The
Committee on Animal Experimentation of the University of
Tokyo, Tokyo, Japan (Approval ID: P10-134).
Induction and evaluation of DSS-induced colitis
C57BL/6 mice were purchased from Clea Japan Inc. (Tokyo,
Japan), bred in a pathogen-free barrier facility and used at 8–12
weeks of age. Three % (w/v) DSS (molecular mass, 36–50 kDa;
Sigma, St. Louis, MO) was dissolved in purified water and
administered to mice instead of normal drinking water for 7 days
[29]. The volume of water intake was measured daily to determine
the amount of DSS consumed per mouse; this was comparable
between treatment groups in all experiments. To analyze the
therapeutic effect of bortezomib (LC Laboratories, Woburn, MA),
0.75 mg/kg was injected in 200 ml PBS through lateral tail veins
twice weekly, starting 2 days before the administration of DSS.
Control animals received an identical volume of PBS alone.
Clinical DAI scoring for DSS-induced colitis was based on
weight loss, stool consistency, and bleeding as described previously
[30]. The DAI was scored on a scale from 0–4 for each clinical
parameter and then averaged for each group. Weight changes
were based on the starting weight of each mouse at the initiation of
DSS treatment. Weight-loss scores were determined as follows: 0,
no weight loss; 1, 1–5% weight loss; 2, 6–10% weight loss; 3, 11–
15% weight loss; and 4, .15% weight loss. Stool samples were
collected from each mouse at all timepoints and stool scores were
determined as follows: 0, normal stools; 2, loose stools; and 4,
diarrhea. Fecal blood testing kits (Shionogi, Osaka, Japan) were
used to check the stools for the presence of blood. Bleeding scores
were determined as: 0, no bleeding; 1, guiaiac occult blood test
(minimal color change to green); 2, guiaiac occult blood test
(maximal color change to blue); 3, blood visibly present in the stool
and no clotting on the anus; and 4, gross bleeding from the anus
with clotting present.
Histologic analysis
Mice were sacrificed 5 days after the induction of intestinal
injury. Colon samples were removed and segments fixed in 10%
Figure 5. Bortezomib treatment reduces IFN-c production by CD4
+ and CD8
+ T cells in mesenteric lymph nodes during DSS-induced
colitis. IFN-c production by mesenteric lymph node CD4
+ (A) or CD8
+ (B) T cells 7 days following DSS administration as determined by intracellular
cytokine staining with flow cytometry analysis. Bar graphs indicate mean (6 SEM) percentages and numbers of draining lymph node IFN-c-producing
CD4
+ or CD8
+ T cells following bortezomib or control treatment in one representative experiment with three mice per group. Significant differences
between PBS-treated mice versus other group are indicated; *P,0.05, **P,0.01. Similar results were obtained in at least two independent
experiments.
doi:10.1371/journal.pone.0034587.g005
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were cut and stained with hematoxylin and eosin. Histologic
scoring was based on a previously described method [29]. Briefly,
hematoxylin and eosin-stained cross-sections of the descending
colon tissue were scored microscopically in a blinded fashion on a
scale from 0–4 based on the following histologic criteria: 0, no
change from normal tissue; 1, low level of inflammation with
scattered infiltrating mononuclear cells (1–2 foci); 2, moderate
inflammation with multiple foci; 3, high level of inflammation with
increased vascular density and marked wall thickening; 4, maximal
severity of inflammation with transmural leukocyte infiltration and
loss of goblet cells. An average of four fields of view per colon were
evaluated for each mouse. These scores were averaged for each
group and recorded as the histopathology score.
For immunohistochemistry, frozen tissue sections of the colon
samples were acetone-fixed and incubated with 10% normal
rabbit serum in PBS for 10 minutes at 37uC to block non-specific
staining. Sections were then incubated with rat mAbs specific for
mouse CD4, CD8, B220 (BD PharMingen; San Diego, CA), and
macrophages (F4/80; American Type Culture Collection; Rock-
ville, MD). Rat IgG (Southern Biotechnology Associates Inc.,
Birmingham, AL) was used as a control for non-specific staining.
Sections were then incubated sequentially for 20 minutes at 37uC
with a biotinylated rabbit anti-rat IgG and then horseradish
peroxidase-conjugated avidin–biotin complex (Vectastain ABC kit;
Vector Laboratories, Burlingame, CA). Sections were developed
with 3,39-diaminobenzidine tetrahydrochloride and hydrogen
peroxide and counterstained with methyl green. Stained cells
were counted in 10 random grids under high-magnification (6400)
power fields of a light microscope. Each section was examined
independently by two investigators in a blinded manner.
Cell isolation
Single-cell suspensions of spleen and mesenteric lymph nodes
were generated by gentle dissection. Magnetic cell sorting tech-
nology (Miltenyi Biotech, Auburn, CA) was used to purify CD4
+
and CD8
+ T cell lymphocyte populations.
Antibodies and immunofluorescence analysis
Anti-mouse mAbs B220 (RA3-6B2), CD4 (H129.19), CD8 (53-
6.7), and CD19 (1D3) were from BD PharMingen. Intracellular
staining used mAbs reactive with IFN-c (XMG1.2), IL-17A
(eBio17B7), and IL-4 (BVD6-24G2), and the Cytofix/Cytoperm
kit (BD Biosciences, San Diego, CA). Single cell suspensions of
draining lymph nodes (paired axillary ad inguinal) were generated
by gentle dissection. Viable cells were counted using a hemocy-
tometer, with relative lymphocyte percentages determined by flow
cytometry analysis. Single-cell leukocyte suspensions were stained
on ice using predetermined optimal concentrations of each
antibody for 20–60 minutes, and fixed as described [31]. For
intracellular cytokine staining, lymphocytes were stimulated in vitro
with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich),
ionomycin 1 mg/ml; Sigma-Aldrich) in the presence of monensin
(1 mM; eBioscience) for 5 hours before staining. In certain
experiments, apoptosis was measured by flow-cytometric staining
for Annexin-V and 7-AAD (BD PharMingen). Cells with
lymphocyte light scatter properties were analyzed by 2–4 color
immunofluorescence staining and FACSCalibur flow cytometers
(Becton Dickinson, San Jose, CA). Background staining was
determined using unreactive isotype-matched control mAbs
(Caltag Laboratories, San Francisco, CA) with gates positioned
to exclude $98% of unreactive cells.
RNA isolation and real-time reverse transcription-PCR
Total RNA was isolated from colon specimens and mesenteric
lymph node suspensions with RNeasy spin columns (Qiagen,
Crawley, UK). Total RNA from each sample was reverse-
transcribed into cDNA. Expression of IL-4, IL-6, IL-10, IL-17,
IFN-c and IkBa was analyzed using a real-time PCR quantifica-
tion method according to the manufacturer’s instructions (Applied
Biosystems, Foster City, CA). Sequence-specific primers and
probes were designed by Pre-Developed TaqMan assay reagents
or Assay-On-Demand (Applied Biosystems). Real-time PCR (40
cycles of denaturing at 92uC for 15 seconds and annealing at 60uC
for 60 seconds) was performed on an ABI Prism 7000 sequence
detector (Applied Biosystems). Glyceraldehyde-3-phosphate was
used to normalize mRNA. Relative expression of real-time PCR
products was determined by using DDCT methods [32] to
Figure 6. Bortezomib treatment enhances T cell apoptosis by
inhibiting NF-kB activation. (A) The percentages of Annexin-V/7-
AAD
+ CD4
+ and CD8
+ T cells in mesenteric lymph nodes 7 days after the
administration of DSS. Bar graphs indicate mean (6 SEM) percentages
of mesenteric lymph node Annexin-V/7-AAD
+ CD4
+ and CD8
+ T cells
following bortezomib or control treatment in one representative
experiment with 4 mice per group. (B)I kBa mRNA expression in
mesenteric lymph nodes CD4
+ and CD8
+ T cells. Transcript levels were
quantified by real-time PCR analysis and were normalized with an
internal control. Values represent means (6 SEM) from $4 mice of each
group. A, B) Significant differences between sample means are
indicated; *P,0.05; **P,0.01. Similar results were obtained in at least
two independent experiments.
doi:10.1371/journal.pone.0034587.g006
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One of the control samples was chosen as a calibrator sample.
Statistical analysis
All data are expressed as mean 6 SEM. The Mann–Whitney U
test was used to determine the level of significance of differences in
sample means, and the Bonferroni test was used for multiple
comparisons.
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